Drug Approval | June 27, 2025
Biocon Biologics receives Health Canada approval for Yesafili
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Rising demands and advancements in eye care drive growth
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Strengthening capabilities in Peptide Therapeutics and CDMO services
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
There are 38.4 million people with diabetes in the United States
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
Subscribe To Our Newsletter & Stay Updated
